ArticleJournal of diabetes investigation2018
Regulation of glucagon-like peptide-1 sensitivity by gut microbiota dysbiosis.
Article in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson's disease.Probiotics and antimicrobial proteins · 2026Review
- Review
- The role of gut microbiota-mitochondria crosstalk in neurodegeneration: Underlying mechanisms and potential therapies.Neural regeneration research · 2026Article
- The Role of Bacteria-Derived Hydrogen Sulfide in Multiple Axes of Disease.International journal of molecular sciences · 2025Review
- Microbiome-Gut-Brain Axis: Implications for the Links Between Inflammatory Bowel Disease and Neuropsychiatric Disorders.Journal of inflammation research · 2025Review
- The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders.Therapeutic advances in neurological disorders · 2025Review
- The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.Medicina (Kaunas, Lithuania) · 2024Review
- Incretin-based therapy: a new horizon in diabetes management.Journal of diabetes and metabolic disorders · 2024Review
- Postoperative delayed gastric emptying: may gut microbiota play a role?Frontiers in cellular and infection microbiology · 2024Review
- Review
- Plasma Prostaglandin EMetabolites · 2022Article
- Anti-inflammatory effects of GLP-1 in patients with COVID-19.Expert review of anti-infective therapy · 2022Review
- Article
- Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.BioMed research international · 2021Review
- Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics.The international journal of neuropsychopharmacology · 2020Article
- The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders.Expert review of neurotherapeutics · 2020Review
- The journey to understanding incretin systems: Theory, practice and more theory.Journal of diabetes investigation · 2019Article
- Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult.Journal of diabetes research · 2019Article
- Diet in Parkinson's Disease: Critical Role for the Microbiome.Frontiers in neurology · 2019Review
Corrections and comments
- Erratum issuedCorrigendum.2022
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota dysbiosis reduces expression of GLP-1 receptor (GLP-1R) and neuronal nitric oxide synthase (nNOS) in the enteric nervous system and hampers GLP-1-induced nitric oxide (NO) production through a pattern recognition receptor (PRR)-dependent mechanism, hence preventing activation of the gut-brain-periphery axis for control of insulin secretion and gastric emptying.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.